Qube Research & Technologies (QRT)
ALNY icon

Qube Research & Technologies (QRT)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$27K – 3525
2025
Q1 		$27K Hold
100
– – ﹤0.01% 3192
2024
Q4 		$23.5K Buy
+100
New +$26.3K ﹤0.01% 3172

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALNY Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.7% in Q2 2026, selling an estimated $11.9M and leaving 798,715 shares worth $240M. The position accounts for 0.22% of the portfolio, ranked #103.

Qube Research & Technologies (QRT) first reported a position in ALNY in Q3 2018 and has held it in 17 quarters since. The position peaked at $370M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Qube Research & Technologies (QRT) held 798,715 shares of Alnylam Pharmaceuticals worth $240M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 39,472 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $11.9M.
  • Alnylam Pharmaceuticals made up 0.22% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #103 holding.
  • Qube Research & Technologies (QRT) first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Qube Research & Technologies (QRT)'s Alnylam Pharmaceuticals position peaked at $370M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.